ESTRELLA IMMUNOPHARMA, INC. Increase (Decrease) in Prepaid Expense and Other Assets
ESTRELLA IMMUNOPHARMA, INC. (ESLA) reported Increase (Decrease) in Prepaid Expense and Other Assets of -$114.66 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-08-13
- ESTRELLA IMMUNOPHARMA, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was -$51.78K.
- ESTRELLA IMMUNOPHARMA, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was -$62.88K.
- ESTRELLA IMMUNOPHARMA, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was -$104.23K, a 136.42% decline year-over-year.
- ESTRELLA IMMUNOPHARMA, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was $232.97K, a 56.48% increase year-over-year.
- ESTRELLA IMMUNOPHARMA, INC. increase (decrease) in prepaid expense and other assets for fiscal 2025 was -$431.19K.
- ESTRELLA IMMUNOPHARMA, INC. increase (decrease) in prepaid expense and other assets for fiscal 2024 was $149.99K.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$51.78K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$114.66K 10-Q · filed 2026-08-13 | -$218.89K derived: sum of 3 quarters · filed 2026-08-13 | $14.08K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$62.88K 10-Q · filed 2026-05-18 | -$167.11K derived: sum of 2 quarters · filed 2026-05-18 | $65.86K derived: sum of 3 quarters · filed 2026-05-18 | -$293.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$104.23K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $128.74K derived: sum of 2 quarters · filed 2026-03-18 | -$230.12K derived: sum of 3 quarters · filed 2026-08-13 | -$431.19K 10-K · filed 2026-03-18 |
| 2025-09-30 | $232.97K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$125.89K derived: sum of 2 quarters · filed 2026-08-13 | -$326.96K 10-Q · filed 2025-11-12 | -$40.74K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$358.86K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$559.93K 10-Q · filed 2026-08-13 | -$273.71K derived: sum of 3 quarters · filed 2026-08-13 | -$124.83K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$201.07K 10-Q · filed 2026-05-18 | $85.15K derived: sum of 2 quarters · filed 2026-05-18 | $234.03K derived: sum of 3 quarters · filed 2026-05-18 | $116.69K derived: sum of 4 quarters · filed 2026-05-18 |
| 2024-12-31 | $286.22K derived: 10-K 6 month − 10-Q 3 month · filed 2026-03-18 | $435.10K 10-K · filed 2026-03-18 | $317.75K derived: sum of 3 quarters · filed 2026-03-18 | $322.61K derived: sum of 4 quarters · filed 2026-03-18 |
| 2024-09-30 | $148.88K 10-Q · filed 2024-11-14 | $31.53K derived: sum of 2 quarters · filed 2025-08-12 | $36.39K 10-Q · filed 2025-11-12 | |
| 2024-06-30 | -$117.35K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$112.49K 10-Q · filed 2025-08-12 | $149.99K 10-KT · filed 2025-03-25 | |
| 2024-03-31 | $4.86K 10-Q · filed 2025-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |